Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Pregabalin for Patients With Irritable Bowel Syndrome
Sponsor: Beijing Tiantan Hospital
Summary
To explore the efficacy of pregabalin for patients with irritable bowel syndrome (IBS).
Official title: Efficacy and Safety of Pregabalin in Patients With Irritable Bowel Syndrome : A Multi-center Prospective Randomized Open Blinded End-point Trial
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
258
Start Date
2026-04-07
Completion Date
2029-03-31
Last Updated
2026-06-25
Healthy Volunteers
No
Conditions
Interventions
The pregabalin group
75 mg twice daily for 3 days, followed by 150 mg twice daily for 3 days during the first week; 225 mg twice daily at week 10; and a tapering regimen at week 12 (150 mg twice daily for 3 days, then 75 mg twice daily for 3 days).
Routine Treatment
Patients also received routine treatment from gastroenterologists. Loperamide: 2-4 mg after each loose stool (max 16 mg/day) to reduce stool frequency, though it does not relieve pain. Rifaximin: 550 mg TID for 14 days (repeatable); or Eluxadoline 100 mg BID (75 mg BID in post-cholecystectomy patients), which is contraindicated in pancreatitis or biliary obstruction. Antispasmodics: Dicyclomine: 10-20 mg QID or Hyoscyamine as needed for cramping.
Locations (1)
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China